Vitamin K2
Menaquinones (MK-4, MK-7) — the 'calcium paradox' vitamin
The mechanism is real: vitamin K activates matrix Gla protein and osteocalcin, which inhibit arterial calcification and support bone mineralisation. But randomised trials of K2 supplementation have largely FAILED to slow vascular calcification or reduce fractures in Western populations. Correcting deficiency matters; supplementing replete people has not been shown to help.
How confident is BioSignal?
Our overall position, and how sure we are of it across each dimension — including where we are not sure at all.
Limited evidence
The mechanism is real: vitamin K activates matrix Gla protein and osteocalcin, which inhibit arterial calcification and support bone mineralisation. But randomised trials of K2 supplementation have largely FAILED to slow vascular calcification or reduce fractures in Western populations. Correcting deficiency matters; supplementing replete people has not been shown to help.
Early or sparse human evidence; conclusions remain uncertain.
Biological Role
Vitamin K is genuinely essential — for clotting factors, for matrix Gla protein (which inhibits calcification), and for osteocalcin (which binds calcium into bone). None of this is in dispute.
Human Evidence
Multiple randomised trials, including in the populations most at risk of calcification. The evidence is not thin — it is substantially negative, which is a stronger and more useful thing.
Supplement Benefit
Trials of K2 for vascular calcification have been essentially null. Fracture evidence outside high-dose pharmacological MK-4 use in Japan is weak.
Broader Claims
Claims that K2 'directs calcium' away from arteries in supplemented humans are mechanistically motivated and not supported by outcome trials.
Safety Confidence
Very well tolerated — with one serious exception. Vitamin K directly antagonises warfarin, and this is a genuine clinical danger rather than a theoretical interaction.
Research Activity
Continuing, though the major calcification trials have already reported and were disappointing.
Where the evidence stands today
How mature the science is, what kinds of evidence exist, and — the part nobody else prints — what is still missing.
7/9
steps proven in humans
Evidence-rich
2 steps not demonstrated: Clinical outcomes · Guideline / regulatory support
Guideline / regulatory support
Not shownNot recommended in cardiovascular or osteoporosis guidelines.
Clinical outcomes
Not shownNo demonstrated reduction in calcification progression or fractures at supplemental doses.
Large human RCTs
ProvenCalcification trials — LARGELY NEGATIVE.
Small human outcome trials
ProvenBone density and calcification markers.
Human safety data
ProvenWell tolerated; serious warfarin interaction.
Human biomarker / pharmacology
ProvenSupplementation reliably improves vitamin K status markers.
Animal
ProvenSupportive.
Cell / in vitro
ProvenWell characterised.
Mechanistic plausibility
ProvenMatrix Gla protein and osteocalcin activation — genuinely strong.
The bottom line
What we know, what we think, what we don't know — and what would change our mind.
What We Know
Vitamin K activates matrix Gla protein, which inhibits calcification, and osteocalcin, which binds calcium into bone. Vitamin K deficiency is associated with worse vascular and bone outcomes. All of this is real.
What We Think
And it still did not work. When K2 supplementation was tested in randomised trials — including in people with heavy calcification and the most to gain — it did not meaningfully slow arterial calcification. This is the most instructive failure on BioSignal: an elegant, true mechanism that simply did not deliver.
What We Don't Know
Why. Whether the calcification process is simply too advanced to reverse by the time it is measurable, whether the doses or durations were wrong, or whether the mechanism matters less in humans than it looks like it should.
Active Research
Chronic kidney disease, where calcification is severe and vitamin K status is often poor — the most plausible remaining population.
What Could Change Our Mind
A positive trial in a genuinely K-deficient, high-calcification population. The trials so far have mostly said no, and they were designed to say yes.
The biggest myth
“K2 supplements slow arterial calcification”
This is where the beautiful mechanism meets the trial data, and loses. Randomised trials of K2 supplementation — including in people with substantial existing calcification, who had the most to gain — have largely failed to show meaningful slowing of calcification progression. This is a tested negative, not an absence of evidence.
Ask BioSignal
Still have a question about vitamin k2?
Answers are retrieved from this record and the rest of the knowledge graph — never generated.
Why people take vitamin k2
Popularity is not evidence — but it is not stupid either. This explains the interest on its own terms.
Vitamin K2 is sold on one of the most elegant mechanisms in nutrition — and it is the clearest case BioSignal can show you of an elegant mechanism failing when it was finally tested. If you understand why K2 didn't work despite being 'obviously' right, you will read every supplement claim differently for the rest of your life.
If you're here because…
Jump straight to the part of the evidence that answers your question.
Approval, safety and regulatory
What it is approved for, who should be careful, what remains unknown — and the limits of what this evidence can tell you.
Regulatory status
Not an approved drug (dietary supplement). Vitamin K itself is used medically for bleeding and in newborns
Availability
Over-the-counter supplement
Sport (WADA)
Not a prohibited class (confirm at publication)
Known safety profile
Vitamin K2 is well tolerated in most people, with no significant toxicity established at supplemental doses. Its one serious safety issue is a drug interaction, and it is a big one.
Common issues
- Generally well tolerated
- Occasional gastrointestinal upset
Use caution if
- People taking WARFARIN — vitamin K directly antagonises the drug and can cause dangerous clotting
- People taking other vitamin K antagonists
- People with clotting disorders (discuss with a clinician)
- People who are pregnant or breastfeeding (supplemental doses; dietary intake is fine)
Long-term unknowns
Long-term supplementation appears safe, though — as with much of this record — the more relevant point is that no benefit has been established that would justify it.
Limits of this evidence
The limitation here is not weak evidence — it is strong evidence pointing the wrong way for the marketing. The calcification trials were designed to demonstrate benefit and did not. That is a more informative result than an absence of trials, and it deserves more weight than it usually gets.
Full regulatory and sport detail
- Regulatory approval
- Not FDA-approved as a drug in supplement form. Vitamin K is used medically to reverse warfarin and to prevent haemorrhagic disease of the newborn.
- Approved indication
- None as a supplement.
- Research chemical
- N/A — a widely available vitamin.
- Sport (WADA)
- Not a WADA-prohibited class — confirm against the current list.
- Publication note
- Re-confirm regulatory status and warfarin-interaction labelling requirements at publication.
Demand, separated from evidence
Every claim people make about this, counted against what the evidence actually showed.
BioSignal evaluated 8 popular claims about vitamin k2.
Here is where each one landed — including the claims of harm, where “not established” is reassuring rather than damning.
- Supported by evidence
- 2
- Mixed evidence
- 1
- Insufficient evidence
- 2
- Not established
- 3
Popularity is not evidence. This is simply a count of every claim BioSignal evaluated on this page, sorted by what the evidence actually showed — the full reasoning behind each verdict is in the Evidence Review below.
Supported by evidence
- Vitamin K activates proteins that inhibit arterial calcification
- Vitamin K deficiency is harmful
Mixed evidence
- K2 prevents fractures
Insufficient evidence
- You should take K2 with your vitamin D and calcium
- MK-7 is better than MK-4
Not established
- K2 supplements slow arterial calcification
- K2 'directs calcium' from your arteries into your bones
- Vitamin K2 is safe for everyone
The evidence review
Every claim with the reasoning behind its verdict, the doses actually studied, where scientists agree and disagree, and the questions still open.
What people claim
Every popular claim, with BioSignal’s verdict and how confident we are in it. The verdicts are always visible; open any claim to read the evidence behind it.
Vitamin K activates proteins that inhibit arterial calcificationSupportedHigh confidence
Established biochemistry. Vitamin K is required to carboxylate matrix Gla protein, the body's principal inhibitor of vascular calcification, and osteocalcin, which incorporates calcium into bone. This is the true premise of the entire K2 story.
K2 'directs calcium' from your arteries into your bonesNot establishedModerate confidence
This is the marketing sentence, and it describes a mechanism rather than a demonstrated outcome. In supplemented humans, the redirection has not been shown to happen in a way that changes calcification or fractures.
K2 prevents fracturesMixedLimited evidence
High-dose pharmacological MK-4 has been used for osteoporosis in Japan with some supportive data, but Western randomised trials of typical supplemental doses have not convincingly demonstrated fracture reduction.
You should take K2 with your vitamin D and calciumInsufficient evidenceLimited evidence
A hugely popular pairing, built entirely on mechanistic reasoning: vitamin D increases calcium absorption, so K2 supposedly ensures it lands in bone rather than artery. There is no outcome evidence that adding K2 to vitamin D changes vascular or fracture outcomes.
MK-7 is better than MK-4Insufficient evidenceLimited evidence
MK-7 has a longer half-life and produces more sustained blood levels, which is why supplements favour it. There is no evidence that this translates into better clinical outcomes — because neither form has convincingly delivered clinical outcomes.
Vitamin K deficiency is harmfulSupportedHigh confidence
Genuine deficiency impairs clotting and is associated with poorer bone and vascular health. Newborns receive vitamin K precisely to prevent life-threatening bleeding. The essentiality is not in question — only the value of supplementing people who are already replete.
Vitamin K2 is safe for everyoneNot establishedHigh confidence
It is well tolerated by most people, but it is genuinely dangerous for one group: anyone taking warfarin. Warfarin works BY blocking vitamin K, so supplementing K2 directly opposes the drug and can cause dangerous clotting. This is not a theoretical interaction — and many K2 labels do not say it plainly enough.
Doses used in human studies
What was actually given to participants in the research. These are descriptions of studies, not recommendations.
Adults (vascular calcification trials)
- Intervention
- MK-7 supplementation
- Dose
- ~180–360 µg/day in trials
- Duration
- 1–3 years
- Outcome
- Progression of vascular/valvular calcification
- Notes
- Trials at these doses and durations largely FAILED to slow calcification. Recorded as the result, not a protocol
Osteoporosis (Japan, pharmacological)
- Intervention
- High-dose MK-4
- Dose
- ~45 mg/day (a pharmacological, not nutritional, dose)
- Duration
- Long-term
- Outcome
- Fracture risk
- Notes
- Roughly 100–250× typical supplement doses. Not replicated in Western trials
Typical supplementation
- Intervention
- MK-7
- Dose
- ~90–200 µg/day in products
- Duration
- Ongoing
- Outcome
- No demonstrated clinical outcome
- Notes
- Well tolerated. NEVER take without medical advice if you are on warfarin
Dietary sources
- Intervention
- Natto, fermented foods, cheese, egg yolk, liver
- Dose
- Variable
- Duration
- Ongoing
- Outcome
- Adequate vitamin K status
- Notes
- Natto is by far the richest natural source of MK-7
Where scientists agree — and don’t
Agreed
- Vitamin K is essential and activates matrix Gla protein and osteocalcin.
- Vitamin K deficiency is associated with worse bone and vascular outcomes.
- Randomised trials of K2 for vascular calcification have been largely negative.
- Vitamin K antagonises warfarin — a genuine clinical danger.
Debated
- Whether any population benefits from K2 supplementation.
- Whether chronic kidney disease, with severe calcification and poor K status, is the exception.
- Whether high-dose MK-4 genuinely reduces fractures.
Unknown
- Why such a compelling mechanism failed to deliver in trials.
- Whether earlier intervention, before calcification is established, would work.
- Whether vitamin K status is a marker of health rather than a cause of it.
What remains unknown
- Why did a mechanism this clean fail this consistently in randomised trials?
- Is arterial calcification simply irreversible once measurable?
- Does anyone benefit — chronic kidney disease, perhaps, where deficiency and calcification are both severe?
- Is low vitamin K a CAUSE of vascular disease, or a marker of the diet and health of people who get it?
Questions people actually ask
Doesn't K2 move calcium out of my arteries and into my bones?
That is the story, and the mechanism behind it is genuinely true — which is exactly what makes this such a valuable example. Vitamin K activates matrix Gla protein, which inhibits calcification in arteries, and osteocalcin, which binds calcium into bone. It is elegant and it is real. But when K2 supplementation was actually tested in randomised trials — including in people with substantial calcification, who had the most to gain — it did not meaningfully slow calcification. The mechanism was right and the outcome did not follow. That happens far more often than the supplement aisle would suggest.
Then why is K2 in every vitamin D product?
Because the reasoning is compelling: vitamin D increases calcium absorption, so it seems obvious that you would want K2 to make sure that calcium ends up in bone rather than in your arteries. It is a good story, and there is no outcome evidence behind it. No trial has shown that adding K2 to vitamin D changes fractures or calcification.
Does K2 prevent osteoporosis and fractures?
Not convincingly at supplement doses. High-dose MK-4 — around 45 mg a day, which is roughly a hundred times what is in a typical capsule — has been used pharmacologically in Japan with some supportive data. Western trials of ordinary supplemental doses have not demonstrated fracture reduction. Resistance training, adequate protein, calcium, and vitamin D have much better evidence for bone.
Is K2 safe?
For most people, yes — it is well tolerated. But there is one situation where it is genuinely dangerous, and it deserves emphasis: if you take warfarin, do not take vitamin K2. Warfarin works by blocking vitamin K, so supplementing it directly opposes your medication and can lead to dangerous clotting. Many K2 labels mention this too quietly, if at all.
So should I stop taking it?
That is your call, and it is a low-risk supplement if you are not on warfarin. What BioSignal can tell you is that the reason you are probably taking it — protecting your arteries — has been tested and did not hold up. If your goal is arterial health, lowering ApoB and blood pressure has overwhelmingly better evidence than any vitamin.
Practical takeaways
- The mechanism is real and elegant: vitamin K activates proteins that keep calcium out of arteries and in bone.
- And it still failed. Randomised trials of K2 supplementation did not meaningfully slow arterial calcification — including in the people with the most to gain.
- This is the clearest lesson on BioSignal: a beautiful mechanism is not a result. That pattern explains most of the supplement aisle.
- The popular 'take K2 with your vitamin D' advice has no outcome evidence behind it — only reasoning.
- If you take warfarin, do not take K2. Warfarin works by blocking vitamin K; you would be fighting your own medication.
How it works
The mechanism comes last on purpose. A compelling explanation of how something might work is the easiest part of the story to tell, and the part most likely to outlive the evidence for it.
Vitamin K is genuinely essential — for clotting factors, for matrix Gla protein (which inhibits calcification), and for osteocalcin (which binds calcium into bone). None of this is in dispute.
How we found out
The Biochemistry
Vitamin K was established as essential for carboxylating clotting factors, matrix Gla protein (which inhibits vascular calcification), and osteocalcin (which binds calcium into bone).
The Calcium Paradox Hypothesis
Observational studies linked higher vitamin K intake with less arterial calcification and better bone health, generating the compelling idea that K2 could redirect calcium from arteries to bone.
The Trials
Randomised trials tested K2 supplementation for slowing vascular and valvular calcification — including in populations with substantial existing calcification — and largely failed to demonstrate benefit.
The Lesson
K2 remains a best-selling supplement, sold on a mechanism that is entirely true and an outcome that has not materialised — the clearest illustration available of why BioSignal grades outcomes rather than mechanisms.
References
Verified sources. BioSignal does not print a citation it has not checked.
References for this record are being verified and will be published with the next review. BioSignal does not print citations it has not checked.
Version history
Version 1.0
Initial record (Editorial Expansion, Batch 3), authored to the Creatine benchmark. Calibration: Established maturity, limited confidence. This record is deliberately framed as BioSignal's canonical mechanism-versus-outcome lesson: the mechanism is real, the trials are negative, and understanding why that is possible is the single most transferable thing a reader can take from this site. The warfarin interaction is elevated because it is a genuine danger. Review cadence: Annually.
Continue exploring
Three places this record leads next.